Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials

被引：0
|
作者：
Nacho Castejón
Kristin Khalaf
Quanhong Ni
Jesús Cuervo
Donald L Patrick
机构：
[1] LA-SER Outcomes,Department of Health Services
[2] C/ Azcárraga 12 A 33010 Oviedo,undefined
[3] Allergan Inc.,undefined
[4] Allergan Inc.,undefined
[5] University of Washington,undefined
来源：
Health and Quality of Life Outcomes | / 13卷
关键词：
Overactive bladder; Urinary incontinence; Utility assessment; Health-related quality of life; I-QOL;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 42 条
  • [1] Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials
    Castejon, Nacho
    Khalaf, Kristin
    Ni, Quanhong
    Cuervo, Jesus
    Patrick, Donald L.
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2015, 13
  • [2] A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the β3-Adrenoceptor Agonist Solabegron for Overactive Bladder
    Ohlstein, Eliot H.
    von Keitz, Alexander
    Michel, Martin C.
    EUROPEAN UROLOGY, 2012, 62 (05) : 834 - 840
  • [3] Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial
    Gotoh, Momokazu
    Yokoyama, Osamu
    Nishizawa, Osamu
    INTERNATIONAL JOURNAL OF UROLOGY, 2011, 18 (05) : 365 - 373
  • [4] OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial
    Chapple, Christopher
    Sievert, Karl-Dietrich
    MacDiarmid, Scott
    Khullar, Vik
    Radziszewski, Piotr
    Nardo, Christopher
    Thompson, Catherine
    Zhou, Jihao
    Haag-Molkenteller, Cornelia
    EUROPEAN UROLOGY, 2013, 64 (02) : 249 - 256
  • [5] Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials
    Kuo, Hann-Chorng
    Lin, Ho-Hsiung
    Yu, Hong-Jeng
    Cheng, Chen-Li
    Hung, Man-Jung
    Lin, Alex Tong-Long
    UROLOGICAL SCIENCE, 2015, 26 (01) : 41 - 48
  • [6] Hengli(R) Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
    Liao, Limin
    Liu, Qinggang
    Cong, Huiling
    Xu, Zhihui
    Li, Enhui
    Weng, Zhiliang
    Jiang, Haihong
    Liu, Ben
    Huang, Xiao
    Xia, Shujie
    Wen, Wei
    Wu, Juan
    Shi, Guowei
    Wang, Yang
    Li, Peijun
    Yu, Yang
    Fang, Zujun
    Zheng, Jie
    Tian, Ye
    Shang, Donghao
    Li, Hanzhong
    Huang, Zhongming
    Zhou, Liqun
    Xiao, Yunxiang
    Zhang, Yaoguang
    Wang, Jianlong
    Zhang, Xiaodong
    Zhang, Peng
    Wang, Dongwen
    Zhang, Xuhui
    Xie, Keji
    Wang, Bin
    Ma, Lulin
    Tian, Xiaojun
    Chen, Lijun
    Dong, Jinkai
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study
    Yoshida, Masaki
    Takeda, Masayuki
    Gotoh, Momokazu
    Nagai, Shinji
    Kurose, Takafumi
    EUROPEAN UROLOGY, 2018, 73 (05) : 783 - 790
  • [8] Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
    Weber, Michael A.
    Haag-Molkenteller, Cornelia
    King, Jennifer
    Walker, Ann
    Mudd, Paul N., Jr.
    White, William B.
    BLOOD PRESSURE MONITORING, 2022, 27 (02) : 128 - 134
  • [9] Efficacy of TAC-302 for patients with detrusor underactivity and overactive bladder: a randomized, double-blind, placebo-controlled phase 2 study
    Yoshida, Masaki
    Gotoh, Momokazu
    Yokoyama, Osamu
    Kakizaki, Hidehiro
    Yamanishi, Tomonori
    Yamaguchi, Osamu
    WORLD JOURNAL OF UROLOGY, 2022, 40 (11) : 2799 - 2805
  • [10] Efficacy of TAC-302 for patients with detrusor underactivity and overactive bladder: a randomized, double-blind, placebo-controlled phase 2 study
    Masaki Yoshida
    Momokazu Gotoh
    Osamu Yokoyama
    Hidehiro Kakizaki
    Tomonori Yamanishi
    Osamu Yamaguchi
    World Journal of Urology, 2022, 40 : 2799 - 2805
12345